Compass Therapeutics Stock Forum

$Compass Therapeutics(CMPX.US)$
NEWS
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
Compass Therapeutics dosed the first patient in the Phase 1 trial of CTX-8371, a novel dual checkpoint blocker targeting PD-1 and PD-L1 in patients with solid tumors. The study aims to evaluate the drug's efficacy in patients who failed prior checkpoint blocker treatments.

Gainers:
• $Livent(LTHM.US)$ +22.58% (it posted better-than-expected quarterly earnings and raised its 2022 revenue forecast)
• $Super Micro Computer(SMCI.US)$ +11.01% (earnings reports)
• $Oatly Group AB(OTLY.US)$ +8.31% (earnings reports)
• $BlueLinx Holdings(BXC.US)$ +9.7% (increases share repurchase authorization to $100 mln; enters into $60 mln accelerated repurchase agreement)
• $Starbucks(SBUX.US)$ +7.18% (matched estimates wi...